RhumbLine Advisers’s Precigen PGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.35M Buy
236,448
+39,041
+20% +$169K ﹤0.01% 2147
2026
Q1
$764K Buy
197,407
+133
+0.1% +$546 ﹤0.01% 2345
2025
Q4
$825K Sell
197,274
-18,495
-9% -$71.6K ﹤0.01% 2342
2025
Q3
$710K Buy
215,769
+17,691
+9% +$49.9K ﹤0.01% 2458
2025
Q2
$281K Buy
198,078
+7,041
+4% +$10K ﹤0.01% 3028
2025
Q1
$285K Sell
191,037
-6,097
-3% -$9.6K ﹤0.01% 2920
2024
Q4
$221K Buy
197,134
+13,338
+7% +$11.4K ﹤0.01% 3138
2024
Q3
$174K Sell
183,796
-18,895
-9% -$23.8K ﹤0.01% 3304
2024
Q2
$320K Sell
202,691
-446
-0.2% -$648 ﹤0.01% 2960
2024
Q1
$295K Sell
203,137
-4,863
-2% -$6.98K ﹤0.01% 2989
2023
Q4
$279K Sell
208,000
-1,054
-0.5% -$1.24K ﹤0.01% 3013
2023
Q3
$297K Buy
209,054
+8,335
+4% +$11.8K ﹤0.01% 2942
2023
Q2
$231K Buy
200,719
+25,336
+14% +$29.9K ﹤0.01% 3163
2023
Q1
$186K Buy
175,383
+21,685
+14% +$31.3K ﹤0.01% 2751
2022
Q4
$234K Buy
153,698
+6,657
+5% +$11.4K ﹤0.01% 2752
2022
Q3
$312K Buy
147,041
+13,494
+10% +$28.5K ﹤0.01% 2711
2022
Q2
$179K Buy
133,547
+35,002
+36% +$51.9K ﹤0.01% 2959
2022
Q1
$208K Sell
98,545
-1,481
-1% -$3.61K ﹤0.01% 2750
2021
Q4
$371K Sell
100,026
-2,069
-2% -$8.9K ﹤0.01% 2630
2021
Q3
$509K Buy
102,095
+3,737
+4% +$21.5K ﹤0.01% 2532
2021
Q2
$641K Buy
98,358
+8,597
+10% +$60.1K ﹤0.01% 2441
2021
Q1
$618K Sell
89,761
-6,675
-7% -$56.4K ﹤0.01% 2391
2020
Q4
$984K Buy
96,436
+7,235
+8% +$46.9K ﹤0.01% 2137
2020
Q3
$312K Sell
89,201
-12,670
-12% -$60.1K ﹤0.01% 2503
2020
Q2
$508K Sell
101,871
-10,050
-9% -$34.2K ﹤0.01% 2337
2020
Q1
$381K Sell
111,921
-2,674
-2% -$11.5K ﹤0.01% 2289
2019
Q4
$628K Buy
114,595
+2,274
+2% +$12.8K ﹤0.01% 2270
2019
Q3
$642K Buy
112,321
+6,732
+6% +$45.7K ﹤0.01% 2235
2019
Q2
$809K Buy
105,589
+10,240
+11% +$55.1K ﹤0.01% 2152
2019
Q1
$502K Sell
95,349
-2,769
-3% -$19.2K ﹤0.01% 2328
2018
Q4
$642K Buy
98,118
+32,785
+50% +$367K ﹤0.01% 2187
2018
Q3
$1.13M Sell
65,333
-2,204
-3% -$32.8K ﹤0.01% 1958
2018
Q2
$941K Buy
67,537
+7,784
+13% +$131K ﹤0.01% 2035
2018
Q1
$916K Buy
59,753
+1,476
+3% +$21.1K ﹤0.01% 1979
2017
Q4
$671K Buy
58,277
+221
+0.4% +$3.29K ﹤0.01% 2110
2017
Q3
$1.1M Sell
58,056
-905
-2% -$18.6K ﹤0.01% 1919
2017
Q2
$1.42M Sell
58,961
-4,090
-6% -$89.7K ﹤0.01% 1770
2017
Q1
$1.25M Buy
63,051
+96
+0.2% +$2.14K ﹤0.01% 1812
2016
Q4
$1.52M Buy
62,955
+5,858
+10% +$163K ﹤0.01% 1609
2016
Q3
$1.59M Buy
57,097
+2,315
+4% +$61.2K ﹤0.01% 1560
2016
Q2
$1.34M Buy
54,782
+7,398
+16% +$210K ﹤0.01% 1608
2016
Q1
$1.59M Buy
47,384
+954
+2% +$30K ﹤0.01% 1522
2015
Q4
$1.39M Buy
46,430
+2,916
+7% +$98.3K ﹤0.01% 1593
2015
Q3
$1.37M Buy
43,514
+1,137
+3% +$55.5K ﹤0.01% 1587
2015
Q2
$2.05M Buy
42,377
+2,476
+6% +$104K 0.01% 1391
2015
Q1
$1.73M Buy
39,901
+9,522
+31% +$342K 0.01% 1504
2014
Q4
$799K Sell
30,379
-419
-1% -$9.19K ﹤0.01% 1963
2014
Q3
$547K Sell
30,798
-1,904
-6% -$38.9K ﹤0.01% 2152
2014
Q2
$785K Buy
32,702
+22,877
+233% +$464K ﹤0.01% 1992
2014
Q1
$247K Buy
9,825
+105
+1% +$2.91K ﹤0.01% 2656
2013
Q4
$221K Buy
+9,720
New +$196K ﹤0.01% 2769

Other funds holding PGEN

RhumbLine Advisers's PGEN Position: Q2 2026 in Review

RhumbLine Advisers increased its Precigen (PGEN) stake by 20% in Q2 2026, buying an estimated $169K and bringing the position to 236,448 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2147.

RhumbLine Advisers first reported a position in PGEN in Q4 2013 and has held it in 51 quarters since. The position peaked at $2.05M in Q2 2015. 211 funds tracked by Wall St. Rank hold PGEN as of Q2 2026.

  • RhumbLine Advisers held 236,448 shares of Precigen worth $1.35M as of Q2 2026.
  • RhumbLine Advisers bought 39,041 Precigen shares in Q2 2026, an estimated $169K.
  • Precigen made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2147 holding.
  • RhumbLine Advisers first reported a position in Precigen in Q4 2013 and has held it in 51 quarters since.
  • RhumbLine Advisers's Precigen position peaked at $2.05M in Q2 2015.
  • 211 funds tracked by Wall St. Rank held Precigen as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.